E-Star BioTech to Begin Phase 2 Trial of MANP in Resistant Hypertension Backed by New Investment

E-Star BioTech, LLC, based in New York, is pioneering the development of innovative peptides for the treatment of cardiovascular, metabolic, and kidney diseases. The company has announced the commencement of a Phase 2 clinical trial for MANP, a peptide designed to treat Resistant Hypertension (BOLD-HTN). This new trial is supported by recent financing and marks a significant step forward for the company.

MANP was originally discovered by Dr. John C. Burnett Jr., who is the Director of the Cardiorenal Research Laboratory at Mayo Clinic. In 2021, E-Star and Mayo Clinic entered into a worldwide exclusive licensing agreement to develop MANP for cardiovascular and metabolic conditions. Over the years, MANP has exhibited a robust safety profile in several Phase 1 studies, which included participants with various forms of Hypertension and Cardiometabolic Syndrome. The upcoming Phase 2 trial will be a randomized, placebo-controlled, double-blind, multi-center study aimed at evaluating the safety and efficacy of MANP in patients suffering from Resistant Hypertension.

Jesse Crowne, the CEO of E-Star, expressed enthusiasm about the collaboration with Mayo Clinic, a globally recognized leader in healthcare and innovation. This partnership is set to leverage the expertise of Mayo Clinic's distinguished clinicians and researchers to advance the development of MANP.

Hypertension affects an estimated 1.28 billion adults aged 30–79 worldwide. Despite the availability of numerous pharmaceutical treatments, only about 21% of hypertensive adults manage to control their condition. Hypertension remains a major cause of premature death globally, both in developed and developing countries. E-Star is committed to improving the health outcomes for the remaining 79% of hypertensive patients and aims to significantly reduce the incidence of premature death associated with this condition.

Mayo Clinic has recently joined ICW Healthcare Ventures as an investor in E-Star. Additionally, Andy Danielsen, Chair of Mayo Clinic Ventures, will be joining E-Star's board of directors. It's also noteworthy that Mayo Clinic has a financial interest in the technology being developed by E-Star, and any revenue generated will be used to support Mayo Clinic's not-for-profit mission, which encompasses patient care, education, and research.

E-Star BioTech, LLC is focused on developing a platform of Natriuretic Peptides for treating Metabolic Syndrome. Its leading asset, MANP, is at the forefront of this innovative approach and is currently under investigation in the ongoing Phase 2 clinical trial. For more information about the company and its projects, please visit their website at https://www.e-star.bio/.